Uloga farmaceuta u zbrinjavanju gojaznih pacijenta
Sažetak
Gojaznost je hronična bolest koja postaje sve češća i predstavlja globalni javno-zdravstveni problem. Povezana je sa većom stopom komorbiditeta kao što su hipertenzija, kardiovaskularne bolesti, dislipidemija, dijabetes i druge.
Farmaceut ima ključnu ulogu u zbrinjavanju pacijenata sa gojaznošću, kao najpristupačniji član zdravstvenog tima. Ova uloga uključuje uvođenje usluga upravljanja gojaznošću kroz detaljne intervjue sa pacijentima, kreiranje personalizovanih terapijskih planova, procenu lekova sa potencijalom za povećanje telesne mase kroz uslugu pregleda terapije, praćenje efikasnosti i bezbednosti lečenja, pružanje relevantnog savetovanja pacijentima i upućivanje pacijenata drugim zdravstvenim profesionalcima kada je neophodno. Gojaznost dovodi do značajnog povećanja volumena distribucije za lipofilne lekove i samo do malog ili umerenog povećanja za hidrofilne lekove. Uticaj gojaznosti na eliminaciju uticaja lekova je relativno mali u poređenju sa uticajem na distribuciju i varira u zavisnosti od specifičnog metaboličkog ili ekskretornog puta.
Reference
Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149-67.
Russell JM, Nick-Dart RL, Nornhold BD. Development of a pharmacist-driven protocol for automatic medication dosage adjustments in obese patients. Am J Health Syst Pharm. 2015;72(19):1656-63.
Barras M, Legg A. Drug dosing in obese adults. Aust Prescr. 2017;40(5):189-193.
The L. Treating obesity and diabetes: drugs alone are not enough. Lancet. 2024;403(10421):1.
Jackson Leach R, Powis J, Baur LA, Caterson ID, Dietz W, Logue J, et al. Clinical care for obesity: A preliminary survey of sixty-eight countries. Clin Obes. 2020;10(2):e12357.
Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic Treatment of Overweight and Obesity in Adults. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905267.
Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875-E891.
Cornier MA. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15 Suppl):S288-S296.
The Agency for Medicines and Medical Devices of Serbia. Medicinal Products. 2024.
Electronic Medicines Compendium (emc). Saxenda 6 mg/mL solution for injection in pre-filled pen, SmPC. 2023.
Christensen ST, Bjerrum OJ. Detection of adverse drug reactions among ordinary users of liraglutide on the occasion of drug dispensing in the community pharmacy setting. J Patient Saf. 2013;9(4):219-23.
Ahmad NN, Robinson S, Kennedy-Martin T, Poon JL, Kan H. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review. Obes Rev. 2021;22(11):e13326.
Hemo B, Endevelt R, Porath A, Stampfer MJ, Shai I. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals. Diabetes Res Clin Pract. 2011;94(2):269-75.
Ko HJ, Kim JW, Lim S. Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting. J Obes Metab Syndr. 2022;31(3):254-262.
Li A, Cunich M, Fuller N, Purcell K, Flynn A, Caterson I. Improving Adherence to Weight-Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support. Obesity (Silver Spring). 2020;28(10):1889-1901.
Mattfeldt-Beman MK, Corrigan SA, Stevens VJ, Sugars CP, Dalcin AT, Givi MJ, et al. Participants' evaluation of a weight-loss program. J Am Diet Assoc. 1999;99(1):66-71.
Kan H, Bae JP, Dunn JP, Buysman EK, Gronroos NN, Swindle JP, et al. Real-world primary nonadherence to antiobesity medications. J Manag Care Spec Pharm. 2023;29(10):1099-1108.
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649.
Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100-109.
Xie Z, Yang S, Deng W, Li J, Chen J. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clin Epidemiol. 2022;14:1463-1476.
Electronic Medicines Compendium (emc). Wegovy 0.25 mg/0.5 mg/1 mg/1.7 mg/2.4 mg FlexTouch solution for injection in pre-filled pen, SmPC. 2023.
Electronic Medicines Compendium (emc). Mysimba 8 mg/90 mg prolonged-release tablets, SmPC. 2023.
Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646-667.
Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399(10321):259-269.
Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022;163(5):1198-1225.
Ganguly R, Tian Y, Kong SX, Hersloev M, Hobbs T, Smolarz BG, et al. Persistence of newer anti-obesity medications in a real-world setting. Diabetes Res Clin Pract. 2018;143:348-356.
Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Curr Obes Rep. 2021;10(1):14-30.
Khalil H, Ellwood L, Lord H, Fernandez R. Pharmacological Treatment for Obesity in Adults: An Umbrella Review. Ann Pharmacother. 2020;54(7):691-705.
Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M. Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview. Diabetes Metab Syndr Obes. 2023;16:1767-1774.
American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S145-S157.
Jordan MA, Harmon J. Pharmacist interventions for obesity: improving treatment adherence and patient outcomes. Integr Pharm Res Pract. 2015;4:79-89.
Mabire L, Mani R, Liu L, Mulligan H, Baxter D. The Influence of Age, Sex and Body Mass Index on the Effectiveness of Brisk Walking for Obesity Management in Adults: A Systematic Review and Meta-Analysis. J Phys Act Health. 2017;14(5):389-407.
Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22 Suppl 3:1-203.
Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43-53.
Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care. 1998;21(3):350-9.
Bramante CT, Lee CJ, Gudzune KA. Treatment of Obesity in Patients With Diabetes. Diabetes Spectr. 2017;30(4):237-243.
Taylor J. Looking Beyond Lifestyle: A Comprehensive Approach to the Treatment of Obesity in the Primary Care Setting. J Nurs Pract. 2020;16(1):74-78.
American Diabetes Association. Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin Diabetes. 2016;34(1):3-21.
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023.
Koliaki C, Spinos T, Spinou M, Brinia Mu E, Mitsopoulou D, Katsilambros N. Defining the Optimal Dietary Approach for Safe, Effective and Sustainable Weight Loss in Overweight and Obese Adults. Healthcare (Basel). 2018;6(3):73.
Higuera-Hernandez MF, Reyes-Cuapio E, Gutierrez-Mendoza M, Rocha NB, Veras AB, Budde H, et al. Fighting obesity: Non-pharmacological interventions. Clin Nutr ESPEN. 2018;25:50-55.
Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, et al. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Curr Obes Rep. 2023;12(4):453-473.
Raynor HA, Champagne CM. Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults. J Acad Nutr Diet. 2016;116(1):129-147.
Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-604.
Rosenthal M, Ward LM, Teng J, Haines S. Weight management counselling among community pharmacists: a scoping review. Int J Pharm Pract. 2018;26(6):475-484.
Alhomoud IS, Cook E, Patel D, Brown R, Dixon DL. Effect of Pharmacist Interventions on the Management of Overweight and Obesity: A Systematic Review. J Am Pharm Assoc. (2003). 2024;64(3):102058.
Leung CW, Epel ES, Ritchie LD, Crawford PB, Laraia BA. Food insecurity is inversely associated with diet quality of lower-income adults. J Acad Nutr Diet. 2014;114(12):1943-53.e2.
Voils CI, Olsen MK, Gierisch JM, McVay MA, Grubber JM, Gaillard L, et al. Maintenance of Weight Loss After Initiation of Nutrition Training: A Randomized Trial. Ann Intern Med. 2017;166(7):463-471.
Butryn ML, Phelan S, Hill JO, Wing RR. Consistent self-monitoring of weight: a key component of successful weight loss maintenance. Obesity (Silver Spring). 2007;15(12):3091-6.
Helander EE, Vuorinen AL, Wansink B, Korhonen IK. Are breaks in daily self-weighing associated with weight gain? PLoS One. 2014;9(11):e113164.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. Endocr Pract. 2017;23(2):207-238.
Thomas JG, Panza E, Goldstein CM, Hayes JF, Benedict N, O'Leary K, et al. Pragmatic Implementation of Online Obesity Treatment and Maintenance Interventions in Primary Care: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(5):502-509.
Greaves CJ, Sheppard KE, Abraham C, Hardeman W, Roden M, Evans PH, et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011;11:119.
Wing RR, Crane MM, Thomas JG, Kumar R, Weinberg B. Improving weight loss outcomes of community interventions by incorporating behavioral strategies. Am J Public Health. 2010;100(12):2513-9.
Yamamoto Y, Ikeue K, Kanasaki M, Yamakage H, Satoh-Asahara N, Masuda I, et al. Age-wise examination of the association of obesity based on body mass index and waist circumference with metabolic diseases in comprehensive health checkup participants. Obes Sci Pract. 2024;10(2):e746.
Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-62.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107.
Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15(1):14-33.
Hu Y, Bao J, Gao Z, Ye L, Wang L. Sodium-Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension. Diabetes Metab Syndr Obes. 2024;17:407-415.
Garrison RJ, Kannel WB, Stokes J, 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16(2):235-51.
Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878-84.
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-26.
Shams E, Kamalumpundi V, Peterson J, Gismondi RA, Oigman W, de Gusmao Correia ML. Highlights of mechanisms and treatment of obesity-related hypertension. J Hum Hypertens. 2022;36(9):785-793.
Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, et al. Hypertension management in patients with cardiovascular comorbidities. Eur Heart J. 2023;44(23):2066-2077.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-62.
Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80-93.
Allcock DM, Sowers JR. Best strategies for hypertension management in type 2 diabetes and obesity. Curr Diab Rep. 2010;10(2):139-44.
Cooper-DeHoff RM, Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010;55(1):61-8.
Lee P, Kengne AP, Greenfield JR, Day RO, Chalmers J, Ho KK. Metabolic sequelae of beta-blocker therapy: weighing in on the obesity epidemic? Int J Obes (Lond). 2011;35(11):1395-403.
Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009;11(6):309-15.
Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S. Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2021;146:36-47.
Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P, et al. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2020;8(3):188-198.
Ma Y, He FJ, MacGregor GA. High salt intake: independent risk factor for obesity? Hypertension. 2015;66(4):843-9.
Kawarazaki W, Fujita T. The Role of Aldosterone in Obesity-Related Hypertension. Am J Hypertens. 2016;29(4):415-23.
Hall ME, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, et al. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2021;78(5):e38-e50.
Soubra L, Elba G. Pharmacist Role in Hypertension Management in the Community Setting: Questionnaire Development, Validation, and Application. Patient Prefer Adherence. 2023;17:351-367.
Reeves L, Robinson K, McClelland T, Adedoyin CA, Broeseker A, Adunlin G. Pharmacist Interventions in the Management of Blood Pressure Control and Adherence to Antihypertensive Medications: A Systematic Review of Randomized Controlled Trials. J Pharm Pract. 2021;34(3):480-492.
Treciokiene I, Postma M, Nguyen T, Fens T, Petkevicius J, Kubilius R, et al. Healthcare professional-led interventions on lifestyle modifications for hypertensive patients - a systematic review and meta-analysis. BMC Fam Pract. 2021;22(1):63.
Wal P, Wal A, Bhandari A, Pandey U, Rai AK. Pharmacist involvement in the patient care improves outcome in hypertension patients. J Res Pharm Pract. 2013;2(3):123-9.
American Diabetes Association. Standards of Medical Care in Diabetes-2019 Abridged for Primary Care Providers. Clin Diabetes. 2019;37(1):11-34.
Grant B, Sandelson M, Agyemang-Prempeh B, Zalin A. Managing obesity in people with type 2 diabetes. Clin Med (Lond). 2021;21(4):e327-e231.
Hughes JD, Wibowo Y, Sunderland B, Hoti K. The role of the pharmacist in the management of type 2 diabetes: current insights and future directions. Integr Pharm Res Pract. 2017;6:15-27.
Alabkal RM, Medlinskiene K, Silcock J, Graham A. Impact of Pharmacist-Led Interventions to Improve Clinical Outcomes for Adults With Type 2 Diabetes at Risk of Developing Cardiovascular Disease: A Systematic Review and Meta-analysis. J Pharm Pract. 2023;36(4):888-899.
Orabone AW, Do V, Cohen E. Pharmacist-Managed Diabetes Programs: Improving Treatment Adherence and Patient Outcomes. Diabetes Metab Syndr Obes. 2022;15:1911-1923.
Nogueira M, Otuyama LJ, Rocha PA, Pinto VB. Pharmaceutical care-based interventions in type 2 diabetes mellitus : a systematic review and meta-analysis of randomized clinical trials. Einstein (Sao Paulo). 2020;18:eRW4686.
Craig HC, Alsaeed D, Norris S, Holian J, Kennedy C, Feldman A, et al. Patient perspectives about treatment preferences for obesity with complications. Obes Sci Pract. 2024;10(1):e720.
Chan DC, Pang J, Watts GF. Dyslipidemia in Obesity. In: Ahima RS, editor. Metabolic Syndrome: A Comprehensive Textbook. Cham: Springer International Publishing; 2016; p. 525-540.
Dias S, Paredes S, Ribeiro L. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. Int J Endocrinol. 2018;2018:2637418.
Cohen JD, Cziraky MJ, Cai Q, Wallace A, Wasser T, Crouse JR, et al. 30-Year Trends in Serum Lipids Among United States Adults: Results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006. Am J Cardiol. 2010;106(7):969-975.
Lamon-Fava S, Wilson PW, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1996;16(12):1509-15.
Fon Tacer K, Rozman D. Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids. 2011;2011:783976.
Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218-40.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.
Klop B, Wouter Jukema J, Rabelink TJ, Castro Cabezas M. A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy. Panminerva Med. 2012;54(2):91-103.
Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011;97(5):350-6.
Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013;61(2):148-52.
Lopez-Miranda J, Williams C, Lairon D. Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr. 2007;98(3):458-73.
Maki KC, Pelkman CL, Finocchiaro ET, Kelley KM, Lawless AL, Schild AL, et al. Resistant starch from high-amylose maize increases insulin sensitivity in overweight and obese men. J Nutr. 2012;142(4):717-23.
Huete L, Manzano-Lista FJ, Aranguez I, Fernandez-Alfonso MS. Impact of pharmacist's intervention on reducing cardiovascular risk in obese patients. Int J Clin Pharm. 2019;41(4):1099-1109.
Charrois TL, Zolezzi M, Koshman SL, Pearson G, Makowsky M, Durec T, et al. A systematic review of the evidence for pharmacist care of patients with dyslipidemia. Pharmacotherapy. 2012;32(3):222-33.
Babadagli HE, Barry AR, Thanassoulis G, Pearson GJ. Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. Can Pharm J (Ott). 2023;156(3):117-127.
Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022;163(3):764-774 e1.
Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol. 2022;20(3):e573-e582.
Feng X, Lin Y, Zhuo S, Dong Z, Shao C, Ye J, et al. Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: A randomized controlled trial. Am J Clin Nutr. 2023;117(4):691-700.
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690.
Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57(12):1711-8.
Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56(4):944-51.
Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, et al. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019;17(13):2776-2784.e4.
Syed-Abdul MM. Expanding Pharmacists' Role in the Management of Non-Alcoholic Fatty Liver Disease. Pharmacy (Basel). 2023;11(5):151.
Gouju J, Legeay S. Pharmacokinetics of obese adults: Not only an increase in weight. Biomed Pharmacother. 2023;166:115281.
Vučićević K, Miljković B. Obesity as a factor of pharmacokinetic variability. Arh farm. 2011;61:365-382.
Vučićević K, Miljković B, Prostran M. Pharmacokinetic considerations in drug dosing to pediatric obese patients. Medical data. 2016;8(3):149-153.
Meng L, Mui E, Ha DR, Stave C, Deresinski SC, Holubar M. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update. Pharmacotherapy. 2023;43(3):226-246.
Velissaris D, Karamouzos V, Marangos M, Pierrakos C, Karanikolas M. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review. J Clin Med Res. 2014;6(4):227-33.
Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277-304.
Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119-33.
Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(18):2037-2048.
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).